IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thompson, et al.	
Serial No. to be assigned Filed: For: 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS	Art Unit: Examiner:
Commissioner for Patents	

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

P.O. Box 1450

Alexandria, Virginia 22313-1450

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

By Date

RELATED APPLICATION

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER	FILING DATE	MERCK CASE			
If this is inconvenient, additional copies will be submitted upon re	equest.				
6. In accordance with 37 C.F.R. 1.97, (check one)					
the attached information is filed within three months of the fili	ng date of the captioned case.				
the attached information is filed more than three months afte Office Action on the merits.	r the filing date but prior to the	mailing of a first			
the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.					
Office Action on the merits, but before the mailing date of a Foundation of the merits, but before the mailing date of a Foundation otherwise closes prosecution in the application. The enclose Account No. 13-2755 for the fee required under 37 C.F.R. 1.	Final Action, Notice of Allowanced authorization is therefore giv	e, or an action that			

Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).

each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.

no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Math.

By: Mitul I. Desai

Attorney For Applicant(s)

Reg. No. 46,661

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-<u>3190</u>

Date: February 14, 2006

WED BORGER OFF OF FER THE

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN			
INFORMATION DISCLOSURE			CLOSURE	Application Number	PCT/US2004/025961		
	STATEMENT BY APPLICANT			Filing Date			
8				First Named Inventor	Thompson, et al.		
				Group Art Unit			
	(use as many sheets as necessary)			Examiner Name			
Sheet	1	of	2	Attorney Docket Number	21494YP		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
.,						

	FOREIGN PATENT DOCUMENTS							
Examiner Cite			Foreign Patent Document		Name of Patentee or Applicant	Date of Publication of		
Initials*	No.	Office	Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY		
	A1		EP 0 641 781 A		Yoshitomi Pharmaceuticals	03/08/1995		
	A2		EP 0 729 758 A		Pfizer Inc.	09/04/1996		
	A3		WO 98/35048 A		Shokat Kevan M.	08/13/1998		

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of

-	bstitute for form 1449B/PTO			COMPLETE IF KNOWN			
INFORMATION DISCLOSURE				Application Number	PCT/US2004/025961		
				Filing Date	6 N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
S	STATEMENT BY APPLICANT			First Named Inventor	Thompson, et al.		
			,	Group Art Unit			
	(use as many sheets	as n	ecessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	21494YP		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
	A4	Anthony C. Bishop, et al. "Design of allele-specific inhibitors to probe protein kinase signaling" Current Biology, Vol. 8, No. 5, 1998, pages 257-266				
-						
		I and the second				

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.